AzTrials
AzTrials

MyelopathyNCT03518164

Comparing Allograft to Autograft Bone in ACDF Surgeries

A study testing Allograft in people with Myelopathy, run by Rutgers, The State University of New Jersey.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

Anterior cervical discectomy and fusion (ACDF) is a surgery performed from the front of the neck in which damaged discs are removed and a bone graft is inserted into the space to allow the bone to grow together to set up a bridge or fusion between the bones of the spine. Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Myelopathy
What is being tested?
Allograft
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
No sites listed yet
Study dates
1 Mar 2020to 25 Aug 2020
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Only two level anterior cervical discectomy surgeries will be considered. Indications for surgery can be myelopathy, radiculopathy, or mechanical neck pain resulting from instability. Patients for this study are individuals who would be undergoing surgery regardless of the clinical study.
  • Age between 18 and 80 years.

Who cannot join

  • Patients who have previously undergone cervical spine surgery, of any kind, will not be permitted to enroll in this study.
  • Patients who require only 1 level of surgery or who require surgery for 3 or more levels may not be enrolled.
  • Surgical issues excluding a patient from enrollment include the need for a corpectomy or the presence of opacification of the posterior longitudinal ligament (OPLL).
  • Patients requiring regular usage of glucocorticoid medications, for any reasons (rheumatological, pulmonary, immunological, endocrinological, etc.) will be excluded.
  • Patients taking non-steroidal anti-inflammatory (NSAID) medications would be required to discontinue their medications 10 days prior to the date of surgery and for a minimum of 6 weeks following surgery. If the patient is unable or unwilling to do this, then that patient would be excluded.

About this study

Official title: A Randomized, Prospective Clinical Trial Comparing the Use of Allograft Bone With Autograft Iliac Crest Bone in Anterior Cervical Spine Fusion Surgeries

Anterior cervical discectomy and fusion (ACDF) is a surgery performed from the front of the neck in which damaged discs are removed and a bone graft is inserted into the space to allow the bone to grow together to set up a bridge or fusion between the bones of the spine. The purpose of this study is to determine whether there is an advantage to using autograft (bone material taken from the patient's own hip) or allograft (bone material derived from other sources) when performing ACDF. Both of these materials are routinely used by surgeons in ACDF surgeries. Neither is experimental.

Subjects who participate in this study will be randomized to receive either allograft or autograft bone for the surgery. They will receive the 2 level ACDF surgeries routinely employed by the surgeons. The same screw-plate fixation will be used for all subjects in the trial and the same allograft material will be used for all subjects who are randomized to the allograft arm of this study.

A determination will be made as to whether there is a difference in fusion rates associated with the choice of either allograft bone or autograft bone based on the subjects' x-rays one year post surgery. The study will also determine whether there are differences in clinical and functional outcomes associated with the choice of bone graft as measured by patient-reported outcomes instruments collected. In addition, the study will examine whether there are differences in clinical and radiographic outcomes based on choice of bone graft for the subgroup of smokers participating in the study. Overall hospitalization costs will also be obtained and compared as an indication as to whether one method or the other may be superior from a financial standpoint.

Read the detailed description

The study is a prospective, randomized multicenter trial. Approximately 200 subjects will be enrolled at 12 sites throughout the United States and Canada. Up to 250 subjects may be enrolled to account for screen failures. Rutgers, New Jersey Medical School is the coordinating center for the study. The purpose of this study is to determine whether there is an advantage to using autograft (bone material taken from the patient's own hip) or allograft (bone material derived from other sources) when performing ACDF. Both of these materials are routinely used by surgeons in ACDF surgeries. Neither is experimental.

Using a computer randomization program, the central study coordinating site will randomize subjects in a 1:1 ratio to either the autograft or allograft arm of the trial. Surgery is then scheduled in the routine manner. The same ACDF surgeries routinely employed by study surgeons will be performed with screw-plate fixation using the same Medtronic system for all surgeries. In addition, all surgeons will use the same allograft struts, also be provided by Medtronic [Cornerstone].

Postoperative management will be the usual and customary procedures followed by the spine surgeons participating in the trial. This would include a wound check at some point in the first two weeks following discharge with clinical and radiographic studies performed at 6 weeks, 3 months, 6 months, 1 year, and 2 years after the index surgery. Baseline and 1 year postoperative X-rays will be collected for the study. As the "gold standard" for the evaluation of fusion is the presence of bridging trabecular bone across an intended fusion interspace as well as the lack of motion between the spinous processes at the treated levels, dynamic plain film radiographs in neutral, flexion and extension will be obtained to determine fusion status. Neuroradiologists will review the subjects' 1 year radiographs. If these images are unable to definitively clarify whether a fusion has occurred at the 1 year time point, then CT scan examinations would be obtained as standard of care to make the determination. Review of these CT scans for the trial would also be performed by a blinded study radiologist. Sagittal and coronal reconstructed views will be generated. All subjects' imaging studies will be reviewed by a Board certified radiologist certified in neuroradiology. The flexion and extension cervical spine radiographs would be obtained to determine motion between the spinous processes and the presence of bridging trabecular bone. This will include preoperative and postoperative (1 year) imaging in which the neuroradiologist will be blinded to the readings of any outside radiologists or surgeons. At 1 year, the neuroradiologist will provide a binomial response of either "fused" or "not fused". Partial fusions will be considered not fused for the purposes of this study. The decision of the blinded neuroradiologist will be final regardless of the surgeon's impressions of the imaging studies.

Subject visits will occur at the patients' standard of care clinical visits at baseline/screening and at 6 weeks, 3 months, 6 months, 1 year and 2 years post-surgery. Study questionnaires and routine physician evaluations will be completed at each of these visits. X-rays will be collected and reviewed at the baseline and 1 year visits. A CT scan will be collected at 1 year only in the event that radiographs cannot determine whether fusion has occurred. Subjects will be monitored for adverse events at each visit.

Complications related to the cervical and the iliac regions will be carefully observed. In the cervical spine, the complications would include: persistent neck pain, persistent arm pain, new neurological findings, instrumentation failure, fusion failure, dysphagia, and voice issues (hoarseness and/or weakness). Specific to the iliac patients, complications related to pain, bleeding, infection, development of meralgia paresthetica, pelvis fracture, or other findings related to the iliac harvest would be catalogued. If reoperation is necessary, this will be recorded on a Report of Second Cervical Surgery as well the reason for the reoperation. Complications such as graft dislodgement, extrusion, or collapse will be noted. Instrumentation failure resulting in screw and/or plate fracture will be recorded. Reoperations for any reason will be identified and specific observation will be made as to whether a pseudoarthrosis was present as the rationale for the reoperation. In addition, clarification as to whether surgery was needed for an adjacent segment issue next to a previously successful fusion will be documented.

Due to concerns with swallowing dysfunction following anterior cervical surgery, all patients in the study will be evaluated prior to the surgery and at routine follow-up time points with the Dysphagia Short Questionnaire (DSQ).

Smokers will be included in the study and their patient-reported status with respect to the level of use of nicotine containing products will be documented at each visit. All smokers will be encouraged to quit smoking prior to the surgeries.

Both disease- specific and general patient outcomes will be analyzed at regular intervals. Outcomes related to neck pain, arm pain, and neurological abnormalities will be assessed. The following patient-reported outcomes measures will be administered to subjects prior to surgery and at 6 weeks, 3 months and 6 months, 1 year and 2 years: DSQ, PROMIS-PF, EQ-5D-5L, NDI, and VAS (arm and neck and iliac crest-if applicable).

Conditions
Myelopathy
Being tested
Allograft
Medical subject headings
Spinal Cord Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AllograftProcedure or surgery

    Bone graft

Study groups in NCT03518164
Study groupRoleWhat they receive
AllograftOtherBone graft
Receives: Procedure: Allograft
AutograftOtherBone from iliac crest
Receives: Procedure: Allograft

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Smoking survey

    smoking

    Measured: 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 May 2018
  2. Study start1 Mar 2020
  3. Primary completion25 Aug 2020
  4. Study completion25 Aug 2020

Why it stopped: Investigator stopped study

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03518164
Sponsor's protocol ID
20170000404
Status last verified
Sep 2021
First submitted
25 Apr 2018
Last updated
24 Sep 2021
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Allograft in people with Myelopathy, run by Rutgers, The State University of New Jersey.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 24 Sep 2021. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Smoking survey (time frame: 2 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Sep 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in